丹红注射液联合巴曲酶治疗急性进展性脑梗死60例疗效观察

目的：观察丹红注射液联合巴曲酶治疗急性进展性脑梗死的疗效。方法：60例发病时间在72h内、病情呈进展性加重的脑梗死患者,随机分为观察组和对照组,每组30例,对照组给予巴曲酶,治疗组在此基础上加用丹红注射液治疗。观察2周后神经功能缺损程度评分、日常生活能力评分及临床疗效。随时记录不良反应。结果：治疗组神经功能缺损评分较对照组下降明显,2组比较差异有统计学意义（P〈0.05）,治疗组日常生活能力评分较对照组明显提高,2组比较差异有统计学意义（P〈0.05）;治疗组显效率及总有效率为50.0%和83.3%,对照组显效率及总有效率为30.0%和66.7%,2组比较有统计学意义（P〈0.05）。且无明显不良反应。结论：丹红注射液联合巴曲酶治疗急性进展性脑梗死安全有效。

Clinical Observation of Danhong Injection combined with Batroxobin Injection for 60 Cases of Acute Evolving Cerebral Infarction

Objective：To observe the clinical effect of Danhong injection combined with batroxobin injection for treating acute evolving cerebral infarction（ECI）.Methods：Sixty patients of acute ECI within 72 hours of onset,were divided into batroxobin injection group （the control group,n=30）,treatment group of Danhong injection combined with batroxobin injection（n=30） randomly.Before and after 2-week treatments,the clinical nervous function defect degree and activities of daily living（ADL）were evaluated respectively.Curative effect and side effects were observed too.Results：There was a significant difference of the clinical nervous function defect degree of the two groups after treatment （P〈0.05）.There was a evident difference of ADL of the two groups after treatment （P〈0.05）.The significant efficacy and total efficacy of combination group（50.0%and 83.30%） were significantly higher than that（30.0%and 66.7%）of the other group（P〈0.05）.There were no obvious side effects in the two groups.Conclusion：Danhong injection combined with batroxobin injection is effective and safe for treating patients with acute evolving cerebral infarction